



Biochemical recurrence after radical prostatectomy: what does it mean?

Rafael Tourinho-Barbosa ^{1,2}, Victor Srougi ^{1,3}, Igor Nunes-Silva ¹, Mohammed Baghdadi ¹, Gregory Rembeyo ¹, Sophie S. Eiffel ¹, Eric Barret ¹, Francois Rozet ¹, Marc Galiano ¹, Xavier Cathelineau ¹, Rafael Sanchez-Salas ¹

¹ Department of Urology, Institut Montsouris, Université Paris-Descartes, Paris, France; ² Divisão de Urologia, Faculdade de Medicina ABC, São Paulo, Brasil; ³ Divisão de Urologia, Universidade de São Paulo, São Paulo, Brasil

ABSTRACT

Background: Radical prostatectomy (RP) has been used as the main primary treatment for prostate cancer (PCa) for many years with excellent oncologic results. However, approximately 20-40% of those patients has failed to RP and presented biochemical recurrence (BCR). Prostatic specific antigen (PSA) has been the pivotal tool for recurrence diagnosis, but there is no consensus about the best PSA threshold to define BCR until this moment. The natural history of BCR after surgical procedure is highly variable, but it is important to distinguish biochemical and clinical recurrence and to find the correct timing to start multimodal treatment strategy. Also, it is important to understand the role of each clinical and pathological feature of prostate cancer in BCR, progression to metastatic disease and cancer specific mortality (CSM).

Review design: A simple review was made in Medline for articles written in English language about biochemical recurrence after radical prostatectomy.

Objective: To provide an updated assessment of BCR definition, its meaning, PCa natural history after BCR and the weight of each clinical/pathological feature and risk group classifications in BCR, metastatic disease and CSM.

ARTICLE INFO

Keywords:

Prostatic Neoplasms; Prostate-Specific Antigen; Prostatectomy

Int Braz J Urol. 2018; **44**: 14-21

Submitted for publication:
December 08, 2016

Accepted after revision:
April 02, 2017

Published as Ahead of Print:
May 29, 2017

INTRODUCTION

Prostate cancer (PCa) is the most common solid-organ male malignancy and second only to lung cancer in mortality in the United States (1). Radical prostatectomy (RP) remains the primary treatment for localized PCa and has been performed for many years with excellent oncologic control. However, approximately 20-40% of patients with clinically localized PCa will present biochemical recurrence (BCR) after RP (2-4).

Prostatic specific antigen (PSA) has been used for detection of recurrent disease for more

than 35 years (5). Right after its introduction as a BCR marker, men with distinct diseases were treated similarly. Over time, it was possible to realize that PSA relapse has different meanings according to clinicopathological features, as Gleason score (GS), PSA doubling time (PSA-DT), clinical stage and surgical margins status. Following this trend, individualized treatments emerged and authors proposed different PSA cut-off to define BCR, aiming to intervene in the best moment of PCa recurrence to achieve best perspectives of cure in each patient. In this way, several BCR criteria were adopted, impairing studies comparison

and the practice of generalist doctors. Attempts to standardize BCR definition have been performed in last years, but there is no consensus at this moment (6, 7).

Despite lack of consensus, PSA remains the main tool to assess disease progression after RP. Conventional imaging appears to be useless for re-staging PCa after RP at an early enough stage, while new image techniques have been developed, mainly in nuclear medicine area (8). The natural history of BCR after surgical procedure is highly variable, but it is important to distinguish biochemical and clinical recurrence and to find the correct timing to start multimodal treatment strategy (9, 10). We reviewed the current medical literature to provide an updated assessment of BCR definition, its meaning, natural history and differences among risk groups.

MATERIALS AND METHODS

A review was performed in July 2016 in Pubmed database, in English language, to identify studies about BCR after RP. Keywords comprised “biochemical recurrence”, “radical prostatectomy”, “definition”, “risk factors”, “nomograms” and “risk groups”. We selected 236 papers related to BCR after RP and most relevant ones were included in this review aiming to assess differences in BCR definition and the role of each clinical and pathological feature as a risk factor for biochemical and clinical relapse. Therapeutic management of BCR was not addressed in this review.

Definition

Strict definition of BCR is important to identify patients at risk for disease progression and to enable comparisons among men submitted to CaP treatment in studies.

In 1994, the American Society for Therapeutic Radiology and Oncology (ASTRO) formed a committee to standardize definition of BCR after external-beam radiotherapy. It led to a Consensus Conference in 1996 and recommendation statement, last reviewed in 2005 (11).

Biochemical failure standardization after RP has been studied in more recent years. In the setting of organ confined disease, PSA is supposed

to reach undetectable value after RP. However, undetectable value is dependent on the assay used in each institution, thus it is not uniform among the studies. Another consideration to be made is that patients get undetectable PSA level approximately 4 weeks after surgery, as serum half-life of PSA is about 3.2 days (12). A rising serum PSA level after achieving undetectable value is the first sign of recurrent disease.

Amling and colleagues analyzed the use of various PSA cut point definitions for determining biochemical progression after RP in 2001. They evaluated the percentage of patients with a continued PSA increase after each cut point to define the most appropriate PSA level to determine disease progression. Progression of PSA rates were 49%, 62% and 72% after reaching PSA levels of 0.2, 0.3 and 0.4ng/mL, respectively. They concluded PSA 0.4ng/mL or greater was the most appropriate cut point to define BCR (13).

In 2003, Freedland and colleagues performed a retrospective survey to determine the ideal cutpoint for defining BCR after RP. A series of cutpoints were examined (0.1-0.5ng/mL). They determined the ideal cutpoint as the lowest PSA level associated with a high risk of PSA progression in 1 years and 3 years. The risk of PSA progression in 1 year and 3 years among patients with postoperative PSA >0.1ng/mL was 36% and 67%, respectively. For PSA levels greater than 0.2ng/mL, these rates were 86% and 100%, respectively. Further increases in the threshold for failure did not increase progression rates. It led them to conclude that PSA greater than 0.2ng/mL would be an appropriate cutpoint to define PSA recurrence after RP (14).

Stephenson and colleagues evaluated metastatic disease progression as primary end-point to determine the best PSA cutpoint for BCR definition. In this multivariate regression analyzes performed in 2006, they concluded BCR defined as a PSA \geq 0.4ng/mL and rising, best explains metastatic disease progression and was proposed as the standard for reporting outcomes after RP (15).

In a similar and recent study with a large cohort, Toussi and colleagues found a single PSA \geq 0.4ng/mL had the strongest association between biochemical recurrence and systemic progression.

This PSA threshold was associated with PSA rising over 5 years in 74% of patients (6).

Recent studies have proposed to consider PSA value lesser than 0.2ng/mL for starting salvage therapy in high-risk patients. Mir and colleagues stratified patients into favorable and unfavorable groups and suggested a PSA cut-point of 0.05ng/mL or greater as a reliable PSA threshold in high-risk patients (7).

The American Urological Association and the European Association of Urology have recommended defining BCR as a serum PSA ≥ 0.2 ng/mL followed by a second confirmatory level (16, 17). The National Comprehensive Cancer Network guidelines does not determine a specific PSA value threshold, but define BCR as rising PSA on 2 or more subsequent occasions (18).

More than fifty BCR definitions can be found in the literature (16). Although a single definition is not appropriate for all PCa patients, it is important to define an explicit recommendation that could be easily followed by clinical practitioner. We think until this moment, PSA ≥ 0.2 ng/mL should be the standard value since it has been the most widespread BCR definition in papers and guidelines and represents a more sensitive threshold to PSA progression.

When does it happen?

Median time to BCR ranges from 20 to 38 months (15, 19). Although BCR occurs more often in first 3 years from RP, longer follow-ups are required whereas a considerable number of patients may recur even after 15 years (20, 21). In a retrospective survey of RP performed from 1982 to 1999 with a median follow-up of 5.9 years, overall BCR (PSA ≥ 0.2 ng/mL) rates in 5, 10 and 15 years were 16%, 28% and 39%, respectively (20). More recently, in a series comprising almost 2.500 patients submitted to RP followed longer than 10 years, authors found BCR (PSA ≥ 0.2 ng/mL) rates of 34.3%, 44% and 52.7% at 10, 15 and 20 years after RP, respectively. Relative risk of BCR following surgery decreased with time, but late PSA increase was not negligible, as BCR rates rose by 18.4% from 10 to 20 years (21).

Many clinical and pathological variables have been shown to indicate the likelihood of BCR

after RP. A single variable is not enough to predict biochemical failure. These variables should be graded into nomograms for accurately predicting BCR. In the most studied nomograms CAPRA-S and Stephenson's nomogram, main variables significantly associated with BCR were preoperative PSA and primary and secondary Gleason grades, followed by seminal vesicle invasion (SVI), positive surgical margins (PSM), extraprostatic extension (EPE) and lymph node involvement (14, 22, 23).

Early detection is necessary to find patients with low-stage disease, while PSM is the only feature that the surgeon can influence. Thus, the 2012 US Preventive Services Task Force recommendation to omit PSA screening from routine primary care for men concerns us, since incidence of local and regional-stage disease has reduced and distant-stage disease has increased (24). Therefore, we can expect patients that once could be cured after RP and now might experience BCR. Regarding PSM, we should be careful in the current scenario where surgeons pursue perfect functional preservation in detriment of oncological outcomes, keeping in mind the latter is the primary endpoint.

What does it mean?

In greatest series about BCR after RP there was no man with local or distant clinical disease without an increase in PSA at the time of progression. Rising PSA is the first sign of disease progression after RP, however it does not necessarily lead men to metastatic disease or cancer mortality in few years (12, 20, 25). This is the key to understand variation among BCR definition. BCR defined as PSA ≥ 0.2 ng/mL presents higher rates of biochemical progression, while clinical progression, assessed by metastatic disease or cancer specific mortality, was more associated with PSA ≥ 0.4 ng/mL (14-16). Regardless the BCR definition, it should not be used as a landmark to start treatments. Although better oncologic outcomes were observed when salvage treatment was administered at lower PSA levels, the correct timing of its administration depends on pathologic features, functional status, quality of life effects and patient's preferences (26-28).

Understanding the natural history of PCa after BCR is pivotal to figure out its meaning. An excellent report of natural history of BCR was given by Johns Hopkins's researchers. They performed a retrospective review of almost two thousand men that underwent RP for localized PCa who had not received adjuvant hormonal treatment before documentation of metastasis. Patients with good response to radiotherapy after BCR were also excluded. After a mean follow-up of 5.3 years, BCR (PSA ≥ 0.2 ng/mL) was observed in 15% of patients at a median time of 2.3 years and 34% of them developed metastatic disease. The median actuarial time to clinically evident metastasis after PSA elevation was 8 years and it was dependent on GS 8-10, PSA-DT <10 months and time to BCR after RP. The likelihood of metastatic disease was 37% in 5 years among those men who had presented BCR. Forty four percent of patients with metastatic disease died due to PCa. Actuarial median time to death after development of metastasis was 5 years. Death time was only influenced by time to metastatic disease after RP (25).

Han and colleagues evaluated 2,091 men submitted to RP without adjuvant radiotherapy for a median follow-up of 5.9 years. Recurrence (PSA ≥ 0.2 ng/mL) was noted in 17% of patients. Overall actuarial 5, 10 and 15 year BCR rates were 16%, 28% and 39%, respectively. Same years rates for metastatic disease were 4%, 11% and 19% and for PCa specific mortality 1%, 4% and 11%, respectively (20).

In a large and multicentric study, Eggener and colleagues used PCa pathological features to predict 15-year cancer specific mortality. In this cohort, overall 15-year PCa specific mortality rate was 7%. The only parameters significantly associated with PCa mortality were primary and secondary Gleason grades, seminal vesicle status and surgery year. Low risk patients with organ confined GS=6 cancer had disease specific mortality substantially less than the risk of death from other causes. Otherwise, PCa specific mortality in men with GS ≥ 8 was higher than 31% at 15 to 20 years, substantially greater than the risk of death from competing causes. Increased risk of PCa mortality was also observed among men

with SVI and lymph node metastasis. Year of surgery was a relevant risk factor with an improved prognosis in contemporary patients. Positive surgical margins and EPE were not significantly associated with PCa mortality (29).

Short time from RP to BCR has also been associated with poor clinical prognosis. Ten-year rate of PCa systemic progression ranges from 10% to 19% for patients who experienced BCR >6 years or <1.2 year after RP, respectively. Although the time interval from RP to BCR is not an independent variable related to prognosis, patients with early BCR have higher GS, greater preoperative PSA levels, faster PSA-DT and more advanced tumor stage, factors associated to systemic progression and PCa mortality (19).

A critical issue in the management of BCR after RP is determining whether a rising PSA reflects local or distant recurrence. The most important factors that predict distant recurrence are pathologic GS, pathologic tumor stage and short PSA-DT (19). At low PSA levels that determine BCR, few imaging studies are under investigation to distinguish the sort of recurrence. Preliminary studies suggest that performing Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with rising PSA can be useful for re-staging PCa, even changing treatment strategies (8). While new technologies have been incorporated in BCR management, stratifying patients into risk groups is still crucial, as it can determine different prognosis and treatments.

Differences among risk groups

Men with PCa have been classified into low-, intermediate- and high-risk Groups for tumor recurrence and disease specific mortality, based on PSA level, clinical or pathological staging and GS. High-risk patients have PSA level ≥ 20 ng/mL or GS ≥ 8 or clinical/pathological stage $\geq T2c$ (30). Lymph-node positive (pN1) and PSM have also been reported as poor prognosis factors.

Risk Group classification predicts biochemical and clinical progression as well as PCa specific mortality and overall survival. The risk of disease progression in these groups has been

validated for patients submitted to RP in many studies. In patients from Mayo Clinic, BCR rates were 2.3 and 3.3-fold greater in high and intermediate-risk in comparison with low-risk patients, respectively. In those patients, mortality rates in high and intermediate-risk patients were greater than 11 and 6-fold over low-risk men (31).

Therefore, it is crucial to understand the role of each clinical and pathologic feature in PCa BCR and disease progression.

Pre-operative Prostate Specific Antigen (PSA) and PSA doubling-time (PSA-DT)

PSA is the main biochemical tool for diagnosing and following patients with PCa. Men with preoperative PSA ≥ 20 ng/mL present a BCR risk 3.7-fold greater than those men with PSA < 6 ng/mL (14, 22, 23). PSA-DT is also a good predictor of distant recurrence and PCa specific mortality after RP. Systemic progression and death from PCa are almost 5-fold more often in patients with PSA-DT < 6 months if compared with PSA-DT > 10 years (19). However, its clinical usefulness is limited since a period of 6 months to 2 years of BCR is required for accurate calculation and sometimes treatment decisions should be taken earlier (29).

Gleason score

Primary and secondary Gleason grades are associated with higher BCR rates and are significant predictors of metastatic disease and PCa specific mortality (12, 19). Gleason score ≥ 8 is associated to BCR 3.3-fold higher than GS=6 (22, 23). The 15-year PCa mortality rates for pathological GS=6, 3+4, 4+3 and 8-10 could be as great as 1,2%, 6,5%, 11% and 37%, respectively. Men with GS=6 have negligible risk of cancer death, in contrast with men with intermediate and high-risk PCa (29).

Extraprostatic extension (EPE)

Extraprostatic extension (pT3a or greater) appears to influence BCR, but it is not an independent factor for cancer specific mortality (22, 23, 29). EPE increases BCR risk 1.5-fold over confined disease. The impact of the degree of EPE has been assessed for various methods, including

Epstein's criteria and Wheeler method (32, 33). Extension of EPE has been shown as an independent predictor of BCR in pT3a prostate cancer, even without PSM. However, the difference between focal and non-focal EPE has no impact in PCa specific mortality or overall survival (34, 35).

Seminal vesical invasion (SVI)

Invasion of the seminal vesicles (pT3b) after RP has historically been associated with a poor prognosis. SVI increases BCR risk in 2.3-fold and PCa specific mortality rates are 22% higher (22, 23, 29). It suggests a poorer prognosis in men with pT3b disease in comparison with pT3a. Although the majority of these men have high-grade disease and worse outcomes, some authors have found a subset of patients with SVI with favorable prognosis. Isolated SVI, with negative surgical margins, negative lymph nodes, lower GS and PSA represents a small portion of men with PCa that has better prognosis (36, 37).

Positive surgical margins (PSM)

PSM alone is not associated with higher risk of PCa mortality, although it increases men's risk of BCR in 2 to 4-fold and need for secondary therapy (38). Some authors have attempted to stratify the number and extent of PSM. Although greater number and extension of PSM are associated with an increased risk of BCR compared to solitary and focal PSMs, its clinical usefulness is limited (39). PSM location is also associated to different BCR rates. Bladder neck margin involvement seems to present greater risk of BCR than other sites (40).

Lymph-node positive

Patients with positive node disease have recurrence rates 1.7-fold greater than negative node disease. Lymph node metastasis can increase PCa specific mortality in more than 40% in long-term follow-up (29). Time to progression is significantly correlated with the number of diseased nodes. Biochemical and clinical relapse time can range from 7 to 28 months and from 24 to 46 months, if we consider patients with one or greater than 2 positive nodes, respectively (41).

Median PCa specific survival in those men can be as great as 12 years. Men with minimal metastatic nodes undergoing RP with meticulous pelvic lymph node dissection may remain free of BCR longer than 10 years (42).

CONCLUSIONS

A non-negligible amount of patient presents BCR after RP. Understanding BCR meaning and providing a single definition will help us to standardize and to compare outcomes among studies. Despite the number of BCR definitions, PSA ≥ 0.2 ng/dL is the most used one. PSA relapse help us to guide clinical practice, but it should not be the only feature to determine the therapeutic approach.

There are many variables related to BCR such as GS, pathological stage, surgical margin and lymph-node status. These variables have to be considered together, as they help us to predict local or distant recurrence. Short PSA-DT (mainly PSA-DT <6 months), GS ≥ 8 , SVI (pT3b) and lymph-node positive appears to be the main factors associated to metastatic disease and PCa mortality. With this in mind, stratifying men with PCa into risk groups is pivotal to define prognosis and treatment. This review provides us an updated assessment of BCR definition and meaning, showing us the differences of BCR rates and clinical outcomes among risk Groups.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016;66:7-30.
2. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Natl Cancer Inst.* 2006;98:715-7. Erratum in: *J Natl Cancer Inst.* 2012;104:423.
3. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. *J Urol.* 2002;167(2 Pt 1):528-34.
4. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. *Urology.* 1996;48:249-60.
5. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, et al. Use of human prostate-specific antigen in monitoring prostate cancer. *Cancer Res.* 1981;41:3874-6.
6. Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? *J Urol.* 2016;195:1754-9.
7. Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. *Eur Urol.* 2014;66:204-10.
8. van Leeuwen PJ, Stricker P, Hruba G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. *BJU Int.* 2016;117:732-9.
9. van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, et al. Timing of curative treatment for prostate cancer: a systematic review. *Eur Urol.* 2013;64:204-15.
10. Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, et al. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. *Eur Urol.* 2016;69:135-42.
11. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys.* 2006;65:965-74.
12. Taplin ME. Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. *Rev Urol.* 2003;5 (Suppl 2):S3-S13.
13. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? *J Urol.* 2001;165:1146-51.
14. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. *Prostate-specific antigen. Urology.* 2003;61:365-9.
15. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. *J Clin Oncol.* 2006;24:3973-8.

16. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. *J Urol*. 2007;177:540-5.
17. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. *Eur Urol*. 2014;65:467-79.
18. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. *J Natl Compr Canc Netw*. 2010;8:162-200.
19. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. *Eur Urol*. 2011;59:893-9.
20. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. *J Urol*. 2003;169:517-23.
21. Liesenfeld L, Kron M, Gschwend JE, Herkommer K. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy. *J Urol*. 2017;197:143-8.
22. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Clin Oncol*. 2005;23:7005-12.
23. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. *Cancer*. 2011;117:5039-46.
24. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. *JAMA*. 2015;314:2054-61.
25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA*. 1999;281:1591-7.
26. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, et al. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol*. 2016;69:728-33.
27. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA*. 2004;291:1325-32.
28. D'Amico AV. Adjuvant versus salvage post-prostatectomy radiation therapy: a critical review of the evidence. *J Urol*. 2013;190:450-1.
29. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. *J Urol*. 2011;185:869-75.
30. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA*. 1998;280:969-74.
31. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. *J Urol*. 2008;179:1354-60.
32. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. *J Urol*. 1993;150:135-41.
33. Wheeler TM, Dilliglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. *Hum Pathol*. 1998;29:856-62.
34. Maubon T, Branger N, Bastide C, Lonjon G, Harvey-Bryan KA, Validire P, et al. Impact of the extent of extraprostatic extension defined by Epstein's method in patients with negative surgical margins and negative lymph node invasion. *Prostate Cancer Prostatic Dis*. 2016;19:317-21.
35. Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, et al. Humphreys E, Walsh PC, Han M. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. *Eur Urol*. 2015;67:342-6.
36. Freedland SJ, Aronson WJ, Presti JC Jr, Amling CL, Terris MK, Trock B, et al. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. *Cancer*. 2004;100:1633-8.
37. Salomon L, Anastasiadis AG, Johnson CW, McKiernan JM, Goluboff ET, Abbou CC, et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. *Urology*. 2003;62:304-9.
38. Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. *Eur Urol*. 2014;65:675-80.
39. Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. *J Urol*. 2009;182:1357-63.
40. O'Neil LM, Walsh S, Cohen RJ, Lee S. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence. *BJU Int*. 2015;116 (Suppl 3):42-8.

41. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol. 2003;169:849-54.
42. Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol. 2004;171:1128-31.

Correspondence address:

Rafael Rocha Tourinho-Barbosa, MD
Rua da Fonte 169, Jardim Bela Vista
Santo André, SP, 09040-270, , Brasil
Telephone: + 55 11 98618-6001
E-mail: rafael.tourinho@hotmail.com